Journal article
Prevention of infant eczema by neonatal Bacillus Calmette-Guérin vaccination: The MIS BAIR randomized controlled trial
LF Pittet, NL Messina, K Gardiner, B Freyne, V Abruzzo, KL Francis, C Morrison, C Zufferey, P Vuillermin, KJ Allen, AL Ponsonby, R Robins-Browne, F Shann, KL Flanagan, R Phillips, S Donath, D Casalaz, N Curtis
Allergy European Journal of Allergy and Clinical Immunology | WILEY | Published : 2022
DOI: 10.1111/all.15022
Abstract
Background: Bacille Calmette-Guérin (BCG) vaccine could play a role in counteracting the rising prevalence of atopic diseases, through its beneficial off-target effects. We aimed to determine whether neonatal BCG vaccination reduces the incidence of eczema in infants. Methods: Randomized controlled trial with 1272 infants allocated to receive BCG-Denmark or no BCG at birth. The primary outcome was the 12-month incidence of eczema based on 3-monthly questionnaires. Eczema was also assessed at a 12-month clinic visit. ClinicalTrial.gov: NCT01906853. Results: The 12-month eczema incidence was 32.2% in the BCG group compared with 36.6% in the control group (adjusted risk difference (aRD) −4.3%, ..
View full abstractGrants
Awarded by Aranday Foundation
Funding Acknowledgements
National Health and Medical Research Council of Australia; The University of Melbourne, The Royal Children's Hospital Foundation and the Murdoch Children's Research Institute; Swiss National Science Foundation; Mercy Health; The Myers Foundation; The European Society of Pediatric Infectious Diseases; The Nossal Institute for Global Health; The Aranday Foundation